Roundup Lawsuit Update January 2023

forbes.com Updated: Aug 18, 2022, 1:26pm

Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors’ opinions or evaluations.

Roundup Lawsuit Update January 2023Getty

Table of Contents

Roundup weed killer is used for both commercial and personal use. You’ve probably used a Roundup product at least once to kill pesky weeds in your yard or garden.

While it’s effective, some studies have shown chemicals within the product may cause cancer. If you’ve been diagnosed with cancer because of or related to Roundup use, you may be able to file a lawsuit against Bayer, Roundup’s current owner, for compensation. What follows is an update on where cases stand today and what you can do to protect yourself.

Roundup History

Roundup, the most popular and profitable weed killer ever sold, uses glyphosate as its most active ingredient. Glyphosate is toxic to most broadleaf plants and grasses. It kills most plants it comes into contact with, instead of targeting certain weeds or plants.

Monsanto, a now defunct company, developed the product. Because glyphosate kills anything it touches, Monsanto developed plant seeds that were genetically modified to resist the damage of Roundup. This is when residential Roundup sales skyrocketed.

However, as the years went on, science questioned the safety of glyphosate. Studies have shown that the chemical might cause illness to humans and cause damage to the environment. The International Agency for Research on Cancer categorizes glyphosate as possibly carcinogenic to humans—essentially, the IARC is saying this toxin may cause cancer.

In 2018, Roundup was purchased by Bayer. By then, consumers had filed thousands of lawsuits linking Roundup to cancer. The most common cancer associated with Roundup is non-Hodgkin’s lymphoma. Bayer committed to begin in 2023 replacing “its glyphosate-based products in the U.S. residential Lawn & Garden market with new formulations that rely on alternative active ingredients.”

Roundup Cancer Lawsuits

Tiếp tục đọc “Roundup Lawsuit Update January 2023”

Popular weedkiller Roundup on trial again as cancer victims demand justice

theguardian.com

Mike sitting in the living room of his Phoenix home. Contemplating what his latest biopsy results will reveal.
Mike Langford in the living room of his Phoenix home, contemplating what his latest biopsy results will reveal. Photograph: Matt Williams/The Guardian

A long list of upcoming trials complicating Bayer’s efforts to escape the costly, ongoing litigation over the health effects of Roundup

Cancer has taken an unrelenting toll on 72-year-old Mike Langford. After being diagnosed with non-Hodgkin lymphoma (NHL) in 2007 he suffered through five recurrences despite multiple rounds of chemotherapy and a stem cell transplant. Now he struggles with chemo-related neuropathy in his arms and legs, and new tests show the cancer is back.

Langford blames his cancer on his longtime use of the popular weed-killing product Roundup, which he applied countless times over decades using a backpack sprayer around his five-acre California property and a vacation lake home. He alleges in a lawsuit that Monsanto, the longtime Roundup maker now owned by the German company Bayer AG, should have warned of a cancer risk.

Last month, a San Francisco judge ruled that Langford’s health is so poor that he is entitled to a speedy hearing of his claims. A trial is set for 7 November in San Francisco county superior court.

“I’ve had it so long. I’m very angry,” Langford told the Guardian a day after doctors biopsied an enlarged lymph node. “The future doesn’t look too terribly promising,” he said, trying to hold back tears. He learned last week that the preliminary biopsy results show a return of NHL.

Tiếp tục đọc “Popular weedkiller Roundup on trial again as cancer victims demand justice”

As Bayer’s Roundup Cancer Costs Accumulate, Questions Linger About the Wisdom of Its Monsanto Merger

By DAVID MEYER Fortune

4:00 AM EDT

Bayer has to pay out $81 million in damages to a man who claims the Roundup weedkiller caused his cancer, a jury ruled Wednesday. In a similar ruling last year, the sum was $289 million, reduced to $78 million on appeal. Since that first verdict, Bayer’s shares have lost 40% of their value—and there are still around 11,300 such cases waiting in the wings. Tiếp tục đọc “As Bayer’s Roundup Cancer Costs Accumulate, Questions Linger About the Wisdom of Its Monsanto Merger”